Normal blood clotting and bone preservation*

Vitamin K2 is far less well known than other vitamins. More recently, research has been crediting it with an increasingly important role, particularly in heart, bone and brain health. In addition, it is more and more the subject of continuous studies and is therefore considered a nutraceutical of great value in clinical and preventive medicine.

K2, or menaquinone, is a fat-soluble vitamin that belongs to the K vitamin family. Vitamin K1, also known as "phylloquinone," is found in plants and is converted to vitamin K2 in the body, so this form is considered the least effective as it depends on conversion to the "most active" form of K2 to provide a ensure significant impact. Another type is vitamin K2 MK-4, found in meat, eggs, and dairy products, and vitamin K2 MK-7, the most studied form of vitamin K, which helps maintain cardiovascular and bone health. It is the most bioavailable product, the fastest absorbed and metabolized by the body. This form of vitamin K is found in "grass-feed" meat (i.e. grass-fed or grazing) or fermented soybeans (natto) typical of the Japanese diet and found in fermented cheeses, and therefore in our modern and western nutrition are difficult to find.

It was "discovered" at the end of the 90s of the last century and since then this "young vitamin" has been developing its particularly important effect on the biochemical level more and more. It is produced by the bacteria of the intestinal flora, which form different groups of molecules, including the long-chain "menaquinones", the most active ones, which, as already mentioned, are found in fermented products such as natto, yoghurt with live cultures, kefir or in "grass-fed" meat happen.

Our dietary supplement uses the vitamin K2-MK7 variant "MenaQ7®", the only clinically proven patent on the market, which is the most widely used in the growing research*. It has various quality certifications (including 2015 at the NutrAward as "Best Functional Ingredient") and is manufactured to the highest safety standards.

Scientific research has shown the valuable beneficial effects of this essential vitamin, particularly (but not limited to) cardiovascular and bone health.
The protective action of vitamin K2 at the cardiovascular level is due to its ability to activate MGP (Matrix Gla protein), which binds calcium circulating in the blood and prevents its precipitation in the form of crystals in the arterial wall, thus preventing the formation of atheromatous plaques along with cholesterol prevented. Since arterial calcification is one of the main cardiovascular risk factors and one of the causes of hypertension in old age, which is also related to reduced vascular elasticity, it is becoming increasingly important to avoid deficiencies in this vitamin, which has the particularity of being calcium to "point" at the bones that help it to calcify, and on the other hand to decalcify the arteries and make them more elastic. Important studies show that “when there is a lack of vitamin K2, the non-activation of MGP can lead to important calcifications of the arteries. However, they also show that this condition can be corrected in patients with diabetes by supplementing with vitamin K2. Vitamin K2/MK-7 has been shown to reduce active matrix Gla protein (MGP) levels and reduce arterial stiffness in healthy people and patients with kidney disease.” These significant studies (which can be found at the end of the presentation are) confirm once again that regular intake of vitamin K2 can be a very important element for prevention and cardiovascular health itself.

In fact, at bone level, it slows down the action of the cells responsible for bone resorption (osteoclasts), while activating osteocalcin, a protein that stimulates the adhesive fixation of calcium to bone tissue and teeth, making them more resistant and flexible. This reduces the risk of skeletal diseases such as osteoporosis. In fact, research has shown a reduction in fracture risk regardless of the level of bone mineralization. In this sense, the synergy of the combination with vitamin D3, as we have deliberately included it in our dietary supplement to make the improvement in bone density even more effective, is particularly evident. Vitamin K2 also helps strengthen cartilage, joints and the spine. More recently, due to its valuable properties, it has been increasingly used in degenerative arthrosis or bone demineralization, such as in the “osteopenia” or “osteoporosis” phase, which physiologically occurs after menopause and reduces the potential risks that result. Especially after menopause, the synergy between vitamins K2 and D3 is a real panacea at the bone and cardiovascular level, since it counteracts the loss of bone density and becomes a precious element important for remineralization. It then becomes effective even with loss of bone density, from the first osteopathy to established osteoporosis, which often occur as typical situations with the decline in estrogen with the onset of menopause in women.

There is plenty of evidence emphasizing the brain functions of vitamin K2 and it has also been shown that vitamin K2 is very important in preventing stroke damage or even counteracting simple "brain aging". It is also particularly valued in the field of "anti-aging" medicine and aesthetics and is known for its other benefits for the skin. In fact, vitamin K2 combats the loss of collagen, firms the skin for a youthful appearance, and helps fight the formation of unsightly wrinkles and "bags" under the eyes.

In the vast universe of food supplements, our food supplement based on vitamins K2 and D3 is the result of numerous scientific studies to support the prevention of cardiovascular diseases and bone health as a nutraceutical that is increasingly recognized and respected by the medical profession.

Cardiovascular Health

Mansour et al. Journal of the American Society of Hypertension. 2017 Aoun et al. BMC Nephrology. 2017
Knapen et al. European Journal of Clinical Nutrition. 2016Knapen et al. Journal of Nutritional Science. 2015
Kurnatowska et al. Polish Archives of Internal Medicine. 2015
Knapen et al. Thrombosis and Haemostasis. 2015
Theuwissen et al. British Journal of Nutrition. 2012
Chatrou et al. Blood Review. 2012
Dalmeijer et al. atherosclerosis. 2012
Peeter's FECM, et al. Calcific aortic valve stenosis: hard disease in the heart. Euro Heart J (2017) 0,1-8.
Thamratnopkoon S et al., "Correlations of plasma desphosphorylated uncarboxylated matrix Gla protein with vascular calcification and vascular stiffness in chronic kidney disease," Nephron. Published online December 13, 2016.
Sardana M et al., "Inactive matrix Gla protein and arterial stiffness in type 2 diabetes mellitus," American Journal of Hypertension. Published online December 7, 2016.

Bone Health

Knapen et al. Osteoporosis International. 2013
Ozdemir et al. Journal Pediatric Hematology Oncology. 2013
van Summeren et al. British Journal of Nutrition. 2009

diseased populations

Mansour et al. Journal of the American Society of Hypertension. 2017
Aoun et al. BMC Nephrology. 2017
Kurnatowska et al. Polish Archives of Internal Medicine, 2015
Calwue et al. Nephrology Dialysis Transplant. 2014
Ozdemir et al. Journal Pediatric Hematology Oncology. 2013
Westenfeld et al. American Journal of Kidney Disease. 2012

Optimum bioavailability

Sato et al. NutritionJournal. 2012
Schurgers et al. Blood. 2007

Nutritional values ​​+ recommended consumption